BackBiolife Solutions Overview
Biolife Solutions Inc

Biolife Solutions Target Price

Where could BLFS trade next? Consensus target price: $31.

Get informed when a big investor buys or sells

+ Follow

Share Price

$35.23

Average Target Price

$31.0012% downside

6 analysts in the last 4 months

High: $31 | Low: $31

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-27Stephens$3112% downsideOpen
2026-07-23JefferiesMatthew Stanton$3112% downsideOpen
2026-07-23H.C. WainwrightYi Chen$3112% downsideOpen
2026-07-23William Blair$3112% downsideOpen
2026-07-22Craig-Hallum$3112% downsideOpen
2026-07-22Lake Street$3112% downsideOpen
2026-01-05Northland Securities$343.5% downsideOpen
2025-11-24H.C. WainwrightYi Chen$329.2% downsideOpen
2025-03-05H.C. Wainwright$3014.8% downsideOpen
2024-11-15StephensJacob Johnson$3014.8% downsideOpen
2024-08-12Craig-HallumMatt Hewitt$3014.8% downsideOpen
2024-04-04JefferiesMatthew Stanton$2237.6% downsideOpen

Biolife Solutions (BLFS) FAQ

Biolife Solutions (BLFS) currently reports a target price of $31. Use the charts on this page to explore Biolife Solutions's target price history and peer comparisons.

Analysts' average 12-month price target for Biolife Solutions is $31, about 12.0% downside from the current share price of $35.23. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $31, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biolife Solutions, and consider following BLFS for alerts when major investors trade the stock.

Biolife Solutions is classified in the Healthcare sector. On target price, it currently shows $31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLFS with unrelated industries.